Johnson & Johnson Venture Arm Backs Francis Medical
Investment supports Francis Medical's push for FDA premarket approval of its Vanquish prostate cancer ablation system.
Updated on Nov. 10, 2026 in Healthcare

Johnson & Johnson's venture capital arm, JJDC, has invested in Francis Medical, a company developing a water vapor-powered ablation system for prostate cancer. The funding amount was not disclosed.
Why it matters
The investment supports Francis Medical's plan to seek FDA premarket approval for the Vanquish system, which would extend its use beyond the targeted tissue ablation covered by its existing 510(k) clearance. It signals continued interest from major healthcare investors in minimally invasive prostate cancer treatments.
Francis Medical raised $80 million in a January 2025 Series C round co-led by Arboretum Ventures and Solas BioVentures. The undisclosed JJDC investment amount and the timeline for FDA premarket approval remain unknown.
The players
Johnson & Johnson Development Corporation (JJDC)
The venture capital arm of Johnson & Johnson, the multinational healthcare company, which invests in early-stage medical technology firms.
Francis Medical
A Minnesota-headquartered medical device company developing the Vanquish water vapor-powered ablation system for prostate cancer.
U.S. Food and Drug Administration (FDA)
The federal agency responsible for reviewing and approving medical devices for safety and effectiveness before they reach the U.S. market.
The details
Francis Medical's Vanquish system uses water vapor power and an ultrasound- and magnet-guided transurethral approach. The company reported its first commercial cases in February, including an ablation of a patient with localized prostate cancer in Austin, Texas, and JJDC's funding will support its premarket approval application and scaling of commercial teams and physician training.
Timeline
January 2025: Francis Medical raised $80 million in Series C funding.
February: Francis Medical reported its first commercial cases.
Summer 2026: VAPOR 2 trial data were published in The Journal of Urology.
Roadmap
Francis Medical's existing 510(k) clearance covers targeted ablation of prostate tissue, while its planned premarket approval application would seek the full prostate cancer management indication. The pending FDA review places the company on the more demanding regulatory path that larger device makers typically pursue for broader treatment claims.
For patients weighing prostate cancer treatments, the Vanquish system is not yet available for the full management indication, so current options remain unchanged until the FDA acts on the premarket approval application. Patients interested in this approach should discuss the status of the device and its clearance scope with their urologist.
The takeaway
Venture funding for devices like Vanquish often signals where clinical evidence is heading before regulators finish their review. Readers should watch for the FDA's decision on the premarket approval, which will determine how broadly the system can be used.
Further reading
For more on how medical device companies move from early funding to regulatory approval, explore Healthcare coverage on Wisevoter.










